Current Rating Overview
On 08 January 2026, MarketsMOJO revised Anuh Pharma Ltd’s rating from 'Sell' to 'Strong Sell', reflecting a deterioration in the company’s overall investment appeal. The Mojo Score declined by 3 points, moving from 31 to 28, signalling increased caution for investors. This rating is a comprehensive assessment based on multiple parameters including quality, valuation, financial trends, and technical indicators.
How Anuh Pharma Ltd Looks Today
As of 21 January 2026, Anuh Pharma Ltd remains a microcap player in the Pharmaceuticals & Biotechnology sector, with a Mojo Grade firmly in the 'Strong Sell' category. The company’s stock performance has been notably weak, with a one-year return of -29.77%, significantly underperforming the broader BSE500 index, which has delivered a positive 4.98% return over the same period. This divergence highlights the challenges the company faces in regaining investor confidence.
Quality Assessment
The quality grade for Anuh Pharma Ltd is assessed as average. While the company has demonstrated some growth in net sales, with a compound annual growth rate of 13.69% over the past five years, operating profit growth has been more modest at 7.18% annually. This indicates that while revenue expansion is occurring, profitability improvements have lagged, raising concerns about operational efficiency and sustainable earnings growth.
Valuation Perspective
From a valuation standpoint, the stock is currently considered attractive. This suggests that, relative to its earnings and asset base, Anuh Pharma Ltd’s shares may be undervalued compared to peers or historical averages. However, attractive valuation alone does not offset the risks posed by weak financial trends and technical signals, which are critical for timing investment decisions.
Financial Trend Analysis
The financial grade is negative, reflecting recent deteriorations in key profitability metrics. The latest half-year results show a troubling decline in profit before tax (excluding other income), which fell by 29.3% to ₹8.94 crores compared to the previous four-quarter average. Additionally, the net profit after tax for the latest six months has contracted by 35.19%, standing at ₹15.91 crores. Return on capital employed (ROCE) has also dropped to a low 15.90%, signalling reduced efficiency in generating returns from invested capital.
Technical Indicators
Technically, the stock is rated bearish. Price momentum has been negative across multiple time frames: the stock declined 1.16% on the latest trading day, with losses of 4.53% over the past week and 7.41% in the last month. The six-month decline of 30% further underscores the downward trend. These technical signals suggest continued selling pressure and weak investor sentiment.
Implications for Investors
The 'Strong Sell' rating indicates that MarketsMOJO currently views Anuh Pharma Ltd as a high-risk investment with limited near-term upside. Investors should be cautious and consider the company’s ongoing financial challenges, weak stock performance, and bearish technical outlook before initiating or maintaining positions. The attractive valuation may appeal to value investors, but the negative financial trends and quality concerns warrant a conservative approach.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Anuh Pharma Ltd’s underperformance is notable. While the broader market has shown resilience, the company’s stock has lagged significantly, reflecting sector-specific or company-specific headwinds. Investors should weigh these factors alongside sector trends when evaluating portfolio exposure.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Summary of Key Metrics as of 21 January 2026
To summarise, the stock’s recent performance metrics are as follows: a one-day decline of 1.16%, a one-week loss of 4.53%, and a one-month drop of 7.41%. Over three months, the stock has fallen 11.27%, and over six months, it has declined 30%. Year-to-date losses stand at 10.11%, with a full-year return of -29.77%. These figures highlight sustained downward pressure on the stock price.
Financially, the company’s negative profit trends and low ROCE indicate operational challenges. The average quality rating suggests some stability but not enough to offset the negative financial and technical outlooks. Valuation remains a relative bright spot but is insufficient to improve the overall investment grade.
Investor Takeaway
Investors should interpret the 'Strong Sell' rating as a signal to exercise caution. The current fundamentals and market data suggest that Anuh Pharma Ltd faces significant hurdles that may continue to weigh on its stock price. Those holding the stock may consider reassessing their exposure, while potential investors should seek further developments before committing capital.
MarketsMOJO’s comprehensive evaluation provides a clear framework for understanding the risks and opportunities associated with Anuh Pharma Ltd at this juncture.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
